ページ内を移動するためのリンクです。

Financial Highlights

*From FY2016, International Financial Reporting Standards (IFRS) is applied.

Key Results (Tables)Click to view graphs.

Consolidated Financial Data

   
FY2017 FY2018 FY2019 FY2020
Revenue JPY billion 1,240.0 1,292.0 1,396.2 1,422.8
YoY 3.7% 4.2% 8.1% 1.9%
Business Profit *1 JPY billion 131.4 120.9 187.2 216.9
YoY (1.3)% (8.0)% 54.8% 15.9%
Profit Attributable to Owners of the Company  JPY billion 112.5 82.5 127.2 148.1
YoY 21.5% (26.7)% 54.1% 16.5%
R&D
Expenses *2
JPY billion 174.0 192.9 215.8 216.8
YoY 14.0% 10.9% 11.8% 0.5%

*1: Business Profit = Revenue - Cost of Sales - Selling, general and administrative expenses + Share of profit of associates - R&D expenses
*2: Excludes impairment losses

   
FY2017 FY2018 FY2019 FY2020
Total Assets JPY billion 2,480.3 2,477.4 2,581.3 2,627.8
Equity JPY billion 1,822.0 1,732.3 1,795.4 1,883.4
Ratio of equity attributable to owners of the Company to total assets % 72.3 68.8 68.4 70.5

Revenue by Geographical Segment

  FY2020 (JPY billion) % of Net Sales
Japan 660.3 46.4
North America 460.8 32.4
Europe 145.9 10.2
Others 155.8 11.0
Total 1,422.8 100.0
Revenue to customers by market.

Revenue by Business Segment

  FY2020 (JPY billion) % of Net Sales
Pharmaceutical business 955.2 67.1
Nutraceutical business 334.1 23.5
Consumer products business 31.3 2.2
Other business 102.3 7.2
Total 1,422.8 100.0
Revenue to customers by market.

Key Management Indicators

 
FY2017 FY2018 FY2019 FY2020
ROE (%) 6.4% 4.7% 7.3% 8.2%
EPS (JPY) 207.6 152.2 234.6 273.2
Annual dividends per share (JPY) 100.0 100.0 100.0 100.0
Payout ratio (%) 48.2% 65.7% 42.6% 36.6%

Key Results (Graphs)Click to view tables.

  • Graph:Revenue

  • Graph:Operating Income

  • Graph:R&D Expenditure

  • Graph:Revenue by Geographical Segment

  • Sales by Business Segment